Double primary recurrent human epidermal growth factor receptor 2-positive breast cancer and esophageal cancer that responded well to chemotherapy

We report a case of double primary recurrent HER2-positive breast cancer and esophageal cancer that responded well to radiotherapy and chemotherapy.
Source: International Cancer Conference Journal - Category: Cancer & Oncology Source Type: research

Related Links:

This study is an important step forward in highlighting C1q as a new prognostic candidate biomarker for a range of carcinomas. Methods Oncomine Database Analysis The expression levels of C1QA, C1QB, and C1QC genes in various carcinomas were analyzed using Oncomine (www.oncomine.org), a cancer microarray database and web-based data mining platform from genome-wide expression analyses (22, 23). We compared the differences in mRNA level between normal tissue and carcinoma. The mRNA expression levels in neoplastic tissues compared to the healthy tissues were obtained as the parameters of p-value 2, and gene ranking in the t...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Conclusion MTDH is pro-oncogenic factor playing multifaceted and diverse roles in cancer progression. Its association and central role in regulating signaling pathways such a MAPK, wnt/β-catenin, PI3K/AkT, NF-κβ pathways in various cancers shows that it plays a vital role in metastasis. MTDH contribution to chemo and radiotherapy resistance provides a new direction for the development of anticancer therapeutics. Multiple mechanisms converge to promote expression of MTDH in cancers. Further studies are therefore warranted to determine whether the elevated MTDH expression has prognostic value for development...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
We examined the following three conditions: DMEM high glucose which contained 4.5 mg/ml glucose, independent of serum, DMEM low glucose which contained 1.0 mg/ml glucose, independent of serum. And, DMEM no glucose which contained 0.0 mg/ml glucose, independent of serum. DMEM is referred to as glucose “free,” however some glucose was actually present due to the FBS. The glucose concentration in the FBS used was 1.04 mg/ml. We calculate 0.0937 mg/ml glucose was present in the media under all conditions due to the addition of serum. Quantification of ROS Levels ROS are widely evaluated in tissue culture using di...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusion.In this cohort of patients with GI cancer with brain metastases, HER2+ status was more common intracranially compared with prior sites of disease. These findings suggest that testing HER2 in patients with GI cancer with brain metastases may lead to additional therapeutic options, regardless of HER2 status in previously examined tissue.Implications for Practice.HER2 amplification is a well‐known driver of oncogenesis in breast cancer, with associated increased risk of brain metastases and response to HER2‐directed therapy. In nongastric gastrointestinal (GI) cancers, HER2 amplification is not common and conse...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Precision Medicine, Cancer Diagnostics and Molecular Pathology, Gastrointestinal Cancer Source Type: research
Abstract Micropapillary carcinoma of the bladder (MPBC) is a variant type of infiltrating urothelial carcinoma, which portends a poor biological behavior in terms of disease stage at first diagnosis and clinical outcome; its peculiar morphology raises issues concerning the ability of tumor detection by imaging techniques and proper biopsy procedure, and the appropriate treatment for non-muscle infiltrating and muscle-infiltrating MPBC remains a matter of debate. On the basis of its established prognostic and therapeutic role in breast and gastro-esophageal cancer in the first instance, the human epidermal growth f...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Mol Clin Oncol Source Type: research
We present a case for the development of an anti-t-Darpp therapeutic agent and outline the unique challenges this endeavor will likely encounter. PMID: 30552871 [PubMed - as supplied by publisher]
Source: Biochemical Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Biochem Pharmacol Source Type: research
CONCLUSION: In this cohort of patients with GI cancer with brain metastases, HER2+ status was more common intracranially compared with prior sites of disease. These findings suggest that testing HER2 in patients with GI cancer with brain metastases may lead to additional therapeutic options, regardless of HER2 status in previously examined tissue. IMPLICATIONS FOR PRACTICE: HER2 amplification is a well-known driver of oncogenesis in breast cancer, with associated increased risk of brain metastases and response to HER2-directed therapy. In nongastric gastrointestinal (GI) cancers, HER2 amplification is not common and c...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
ConclusionsDIA is a reliable and feasible alternative to manual HER2 IHC scoring in gastro‐oesophageal adenocarcinoma, both in biopsies and surgical specimens, leading to a reduction of 2+ cases for which subsequent ISH testing is required.This article is protected by copyright. All rights reserved.
Source: Histopathology - Category: Pathology Authors: Tags: Original Article Source Type: research
Results from an open-label, phase 2, basket trial assessing the clinical activity of neratinib in 141 patients with either HER2-mutant or HER3-mutant tumours were presented by David Hyman (Memorial Sloan Kettering Cancer Center, New York, NY, USA). Patients with HER2-mutant lung cancer (n=26), breast cancer (n=25), bladder or urinary tract cancer (n=16), colorectal cancer (n=12), biliary tract cancer (n=9), endometrial cancer (n=7), cervical cancer (n=5), gastro-oesophageal cancer (n=5), and ovarian cancer (n=4), as well as patients with solid tumours not otherwise specified (n=32; of which 15 were HER2-mutant-postive and ...
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Tags: News Source Type: research
ConclusionsLJM716 was well tolerated in Japanese patients, and a degree of tumor shrinkage was observed.Clinical trial informationClinicalTrials.gov NCT01911936.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cardiovascular & Thoracic Surgery | Chemotherapy | Conferences | CT Scan | Docetaxel | Esophagus Cancer | HER2 | Herceptin | Mastectomy | PET Scan | Taxotere